Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Health

Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels at Russian trial -Ifax

FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS

Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.

Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit.

(Reporting by Alexander Marrow; editing by John Stonestreet)

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.